RxDoctor Payments Data

Srinivas Murali

Advanced Heart Failure and Transplant Cardiology · Pittsburgh, PANPI 1316921877

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boehringer Ingelheim at 25.5% of the total. Reporting peaked in 2019 at $12,560 and has fallen 99.9% since, to $14 in 2024.

$39,488in general payments, 2019–2025

Across 82 payments — averaging $481.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$10K
  • Pfizer$8K
  • Novartis$6K
  • Lilly USA, LLC$6K
  • Impulse Dynamics (USA) Inc.$3K
  • Medtronic$2K
  • plus $5K from 16 others
$125,580in research payments, 2019–2025

Across 59 payments — averaging $2128.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cvrx, Inc.$90K
  • Pfizer$36K

What the payments were for

  • Consulting fees$7,53619%
  • Speaking & faculty fees$20,44052%
  • Travel & lodging$8,78722%
  • Food & beverage$2,6227%
  • Education$1020%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,488 in reported general payments places this provider in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$12,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$5,500$12,51412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →